Formei

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Formei

Quick Facts

Property Description
Active ingredient Clotrimazol
Form Cream, Solution, Vaginal Tablets, Pessaries
Pharmacological class Antifungal (Azole Derivative)
Common use Addresses superficial fungal infections
Origin Synthetic

What is Formei? Identity, Classification, and Composition

Formei is a medicinal preparation defined by its active ingredient, Clotrimazol. This drug is classified as an Azole antifungal agent, falling under the larger category of Antimycotics. The substance itself is a synthetic imidazole derivative created through pharmaceutical processes, rather than derived from natural sources.

Formulation of Formei is typically a single-ingredient product, meaning only Clotrimazol provides the primary therapeutic effect. This preparation is clinically recognized for its robust ability to inhibit fungal growth by interfering with cell membrane integrity. The product is manufactured using various inactive bases/vehicles—such as lipophilic bases in creams or hydro-alcoholic solutions in liquids—which determine the final presentation.

Formei's Preparations and General Therapeutic Purpose

Formei is supplied in targeted topical or vaginal dosage forms, including a cream, a solution, vaginal tablets, and pessaries, allowing for direct, localized application. This ensures that the medicine is administered by the topical or vaginal route, maximizing its effectiveness at the site of infection for both dermatological and gynecological applications.

The general therapeutic purpose of Formei is directly tied to its antifungal classification: it is designed to relieve the issues associated with various superficial fungal infections by actively controlling or eliminating the causative fungal organisms. Clotrimazol is widely recognized for its established efficacy against the most common yeasts and dermatophytes that cause these infections.

Regulatory References

  1. Clotrimazole Mechanism of Action (NCBI/NIH)
  2. FDA Clotrimazole Topical Monograph

What side effects are possible with Formei?

Possible Side Effects and Safety Information for Formei

Adverse reactions associated with Formei are cataloged and monitored based on data collected from clinical trials and ongoing post-marketing surveillance, consistent with official regulatory standards (e.g., those from the FDA and EMA). These events are formally classified by frequency and System-Organ Class to ensure comprehensive risk communication.

Adverse Reactions and Frequency

Adverse reactions are grouped by the body system affected and assigned a frequency category, typically adhering to international guidelines:

  • Very Common (ge 1/10)
  • Common (ge 1/100 to < 1/10)
  • Uncommon (ge 1/1,000 to < 1/100)

These reports span multiple System-Organ Classes, including but not limited to, disorders of the gastrointestinal system, nervous system, and skin and subcutaneous tissues.

Serious and Clinically Significant Events

A Serious Adverse Event (SAE) is defined by regulatory bodies as an outcome that results in death, is life-threatening, requires or prolongs hospitalization, or results in persistent or significant disability. The official labeling highlights specific serious and clinically significant reactions that have been identified, requiring close monitoring and timely reporting by manufacturers to governing authorities, such as the FDA Adverse Event Reporting System (FAERS).

Safety Restrictions and Monitoring

Safety documents may detail specific safety-related restrictions or limitations on the drug's use to ensure the risk-benefit profile remains favorable. These restrictions can include mandatory warnings, such as those that appear in Boxed Warnings in the U.S. label, or the need for specific patient monitoring protocols. Furthermore, the safety profile may necessitate specific management measures for certain populations, such as patients with known pre-existing conditions or, in some cases, women of childbearing potential, as outlined in official risk management plans.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is required for any suspected overdose of Formei. Patients or caregivers should contact a doctor, hospital emergency department, or a Poison Control Centre immediately, even if no symptoms are currently present.

Overdose effects are primarily driven by the Amlodipine and Lisinopril components and reflect the extreme extension of their known pharmacological actions. An overdose of the amlodipine component can lead to profound hypotension (severely low blood pressure) resulting from excessive blood vessel dilation, possibly accompanied by reflex tachycardia (abnormally rapid heart rate). Overdosage of the lisinopril component is likely to cause excessive and sustained hypotension and may be associated with elevated levels of potassium in the blood, known as hyperkalemia.

For the atorvastatin component, official regulatory documents state there is no specific treatment available for overdose. Management of the combination product overdose is focused on providing immediate support for the cardiovascular system. This includes frequently monitoring blood pressure, heart and lung function, and, if needed, administering intravenous fluids or vasopressors to stabilize circulation. Due to high protein binding, hemodialysis is unlikely to enhance the clearance of both amlodipine and atorvastatin.

Therapeutic Uses of Formei

What Formei Treats: Main Uses and Benefits

Formei is commonly used across therapeutic domains involving superficial fungal infections, which are conditions presenting with systemic or localized discomfort. This medication helps address symptom clusters that may become intense or disruptive in two primary areas.

For dermatological applications, Formei is considered relevant for easing symptoms linked to conditions such as Athlete's Foot, Ringworm, and fungal rashes in skin folds. It is applied in clinical settings that involve acute or unstable symptom patterns, helping to manage symptoms that interfere with daily functioning, including localized itching, burning, redness, and scaling. This application contributes to easing the overall symptom load and helps improve day-to-day comfort.

For gynecological use, the medication supports symptomatic relief in conditions involving episodic or fluctuating manifestations, specifically Vulvovaginal Candidiasis (Vaginal Yeast Infection). It is used to help with challenging symptoms, including acute localized soreness, pruritus, and burning. This symptomatic assistance supports the patient during difficult episodes by easing distress and assisting with maintaining functional stability.

Quick Fact: Symptom Management
Primary Focus: Supports management of disruptive symptoms in localized mycoses.
Key Benefit: Contributes to easing intense itching and burning sensations.
Usage Context: Applied during phases when acute symptoms become more noticeable.

Eligibility and Restrictions for Use

Eligibility for Formei: Official Regulatory Information

The eligibility for a prescription medicine like Formei is formally defined by government regulatory agencies (such as the FDA, EMA, and Health Canada) to ensure safe use within the authorized population. The official labeling establishes specific conditions and patient groups that legally restrict or prohibit the use of the medicine.

Eligibility Status Patient Group Defined by Official Labeling
Contraindicated Individuals with documented hypersensitivity to the active substance or any ingredient in the formulation.
Use Not Established Pediatric patients (children under 18 years of age), as clinical data is often insufficient to establish safety and efficacy for this group.
Requires Restriction Patients with pre-existing, severe impairment of key organs, such as end-stage renal disease or severe hepatic dysfunction.
Physiological Status Women who are pregnant or breastfeeding, for whom use is officially not recommended or contraindicated unless a doctor determines the potential benefits outweigh all risks.

Official regulatory documents define the allowed population as those who are not subject to any contraindications or restrictions listed in the product's Summary of Product Characteristics (SmPC) or Prescribing Information. Exclusion is mandatory when a patient's characteristics align with a formal contraindication specified by the authorizing body.

What should I know about interactions with other medicines?

The official regulatory profile for Formei (Clotrimazol) administered via the topical or vaginal route is primarily defined by low systemic absorption, which results in minimal documented risk for most classic systemic drug–drug interactions (DDIs).

Local and Functional Interactions

The primary documented interaction is a local effect: the inactive ingredients in the cream and vaginal formulations may cause physical damage to latex or rubber contraceptive barriers, such as condoms and diaphragms, thereby reducing their functional efficacy. To mitigate this risk, regulatory agencies advise the use of alternative precautions for at least five days following the use of this product when relying on these barrier methods. Additionally, co-administration with other intravaginal products, including tampons, douches, and spermicides, should be avoided.

Pharmacokinetic Interaction Risk

Due to Clotrimazol’s enzyme-inhibitory potential, co-administration with the oral immunosuppressants Tacrolimus or Sirolimus might lead to increased plasma levels of these specific medicines. This interaction is formally acknowledged in regulatory documents, which advise that the patient's plasma levels of the immunosuppressant should be monitored if co-administered. For all other systemic medicines, the risk of clinically relevant DDIs is considered negligible, consistent with the minimal concentration of the active ingredient in the bloodstream.

Mechanism of Action

Disruption of Fungal Cell Membrane Synthesis

Formei's active substance, Clotrimazol, acts at the molecular level by selectively inhibiting the fungal enzyme Lanosterol 14-alpha-demethylase (CYP51). This enzyme is crucial for the Ergosterol Biosynthesis Pathway, which is required for the synthesis of the fungal cell membrane. Clotrimazol's binding blocks this enzymatic step, preventing the formation of essential ergosterol while causing the pathological accumulation of dysfunctional or toxic intermediate sterols within the fungal organism.

️ Inducing Cellular Instability and Collapse

The resulting depletion of ergosterol and the accumulation of toxic compounds directly compromise the structural integrity and permeability of the fungal cell membrane. This mechanistic cascade causes the membrane to become porous and unstable, leading to the leakage of vital intracellular components, such as potassium ions and amino acids. This cellular disruption is the core physiological consequence, resulting in the cessation of replication or the collapse of cellular processes in the fungal organism. The mechanism is highly selective as it targets the ergosterol pathway, which is absent in human cells.

Dosage and Administration Information

How to Use Formei: Official Administration Guidelines

Formei, which contains Clotrimazol, is administered through strictly defined topical (dermal) or vaginal routes. The medicine is not intended for systemic use, such as swallowing, and is applied only to the specific areas indicated.


Administration Routes and Dosage

Administration Route Frequency and Course Duration Labeled Dosing Regimen
Topical (Cream/Solution 1%) Twice daily (e.g., morning and evening), typically for 2 to 4 weeks. Apply a thin layer to the affected skin and the immediately surrounding area.
Vaginal (Tablets/Pessaries) Once daily at bedtime, for fixed courses of 1, 3, 6, or 7 days. Dosage ranges include 500 mg (single dose) or 100 mg once daily for 6 or 7 consecutive days.

Procedural and Contextual Usage

The usage of Formei is governed by precise procedural requirements. Topical formulations must be gently massaged into the skin, while contact with the eyes is prohibited. Vaginal products are typically inserted using a dedicated applicator, positioned as high as possible into the vagina, usually when the patient is lying down.

For most conditions, the medicine must be applied for the full duration of the specified treatment course, even if the symptoms begin to resolve earlier. If a dose is missed, it should be applied as soon as it is remembered, with the full treatment course still requiring completion. The labeling establishes the topical administration pattern for use in children over 3 years of age, though no specific dose adjustments are typically required for older adults. The administration method is strictly non-oral and must adhere to these protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Formei (Clotrimazol)


Evidence for Use in Superficial Skin Fungal Infections

The clinical evaluation of Clotrimazol for localized fungal conditions, such as Athlete's Foot and Ringworm, was observed in short-term randomized controlled trials (RCTs), alongside data derived from extensive clinical experience. These studies primarily focused on adults and adolescents with common, uncomplicated infections. Research protocols were designed to monitor two main types of outcomes: measurements of Clinical Cure, which involved tracking outcomes linked to inflammatory or irritative states (such as redness and scaling), and measurements of Mycological Cure, involving laboratory assessment for fungal absence.

Studies conducted during periods of increased symptom activity reported patterns observed in the studies involving patient-reported outcomes describing perceived discomfort. Studies reported patterns of changes in symptom intensity in the weeks immediately following the initiation of treatment. Many studies are available for this medicine, reflecting its long history of use. However, findings indicate that the results apply only to the populations studied and that follow-up durations were limited in many of the key trials.


Evidence for Use in Vaginal Yeast Infections

Research exploring the medicine's use for Vulvovaginal Candidiasis includes multiple randomized controlled trials and systematic reviews. This research examined different clotrimazol regimens in postmenarcheal women with symptomatic infections. Researchers monitored for Therapeutic Cure (defined by researchers as meeting specific criteria for both symptom and laboratory assessments).

Studies focused on episodes where symptoms become more noticeable and explored how measurements of Therapeutic Cure rates compared between different regimens. While data show patterns related to short-term clearance, the research exploring the role of the medicine against uncommon fungal species or in cases of frequent recurrence is ongoing, and data are still emerging for these complex situations.


Research in Specific Groups and Populations

Formei was evaluated in studies involving specific subgroups. Topical formulations was studied for use in children with superficial fungal infections, and specific trials were observed in symptomatic pregnant women for vaginal candidiasis. The inclusion of these groups in research provides information for its use across a broader demographic spectrum. However, data for certain groups remain insufficient, and evidence is limited regarding patients with extensive underlying health conditions or immune-compromised states.

Key Studies & References

  1. Review of Clotrimazole Use in Special Populations: Pediatric and Pregnancy Data (Supporting Specific Groups Section)

Frequently Asked Questions (FAQ)

Common questions about Formei (FAQ)


Q: Do you need a prescription to get Formei?

A: Formei (Clotrimazol) is commonly available for purchase as an over-the-counter (OTC) medicine in topical creams, solutions, and lower-strength vaginal forms. However, certain prescription-strength products or formulations that combine the active ingredient with other medicines may require a prescription (Rx) for purchase. The regulatory status depends on the specific formulation and dose.


Q: Is Formei considered a controlled substance?

A: No, Formei (Clotrimazol) is not classified as a controlled substance by government regulatory agencies. This classification indicates that the medicine is not subject to the special scheduling laws that govern drugs with a potential for abuse or dependency.


Q: Can Formei be taken by children?

A: Official product labeling indicates that topical formulations of Formei are generally included in the authorized population for use in children who are 3 years of age and older for localized fungal infections. Use of vaginal formulations is usually restricted and may not be recommended for those under 12 years of age.


Q: Is Formei safe for people with kidney problems?

A: Because Formei is administered topically or vaginally, only a minimal amount of the active ingredient is typically absorbed into the bloodstream. Due to this minimal absorption, specific dose adjustments related to kidney function are not typically addressed in the regulatory information. However, official regulatory labeling may contain restrictions or recommend monitoring for patients with severe renal impairment.


Q: Can you take Formei if you have liver disease?

A: Systemic absorption of Formei is minimal. Consistent with minimal absorption, the labeling may recommend periodic assessment of liver function in patients with pre-existing hepatic impairment.


Q: What are the signs of a severe allergic reaction to Formei?

A: Signs of a serious allergic reaction, which is a rare event, can include swelling of the face, lips, tongue, or throat, or difficulty swallowing or breathing. Other serious signs may be severe dizziness, fainting, or a widespread skin rash with blistering. The appearance of these symptoms is an event that should be urgently reported to a healthcare provider.


Q: What should I do if I accidentally take too much Formei?

A: Official product information states that the risk of acute overdose from using the product as directed is not a concern due to minimal systemic absorption. Regulatory guidance notes that accidental ingestion is an event that warrants contact with a healthcare provider or a poison control center.


Q: Can I crush or split Formei tablets?

A: The administration instructions for vaginal tablets or pessaries usually require the tablet to be inserted whole, often using the dedicated applicator. The regulatory label does not provide instructions for altering the tablet, such as crushing or splitting, and notes that the product should be used as supplied.


Q: Does Formei cause weight gain or weight loss?

A: Official regulatory product information does not list any significant changes in body weight, such as weight gain or weight loss, as a common, uncommon, or rare adverse reaction associated with Formei.


Q: Is headache a common side effect of Formei?

A: Headache is not typically listed as a common or very common side effect for topical or vaginal Formei in the official product information. In some regulatory documents, headache may be listed among the rare side effects or those where the incidence is not precisely known.


Q: Can Formei cause drowsiness or affect driving?

A: Official regulatory product information does not typically list drowsiness as a common side effect of Formei. As a result, there are no specific warnings in the labeling regarding driving or operating machinery while using the medication.


Q: Is it normal to feel a little dizzy after starting Formei?

A: Dizziness is not commonly reported as a side effect with topical or vaginal use of Formei. However, official safety documents indicate that severe dizziness may be listed as a symptom associated with a rare, serious allergic reaction, requiring immediate medical evaluation.


Q: Is Formei known to cause stomach upset?

A: Gastrointestinal disorders, which can include stomach pain or discomfort, are sometimes listed among the less common or rare side effects associated with the intravaginal use of Formei. These effects are typically local in nature.


Q: Can Formei cause hair loss?

A: Hair loss, also known as alopecia, is not listed as a common or typical side effect in the official regulatory product information for Formei (Clotrimazol).

How should Formei be stored and disposed of?

Official Regulatory Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of Formei to maintain its quality and ensure safety. These instructions are mandatory and non-advisory.

Storage and Disposal Requirement Official Classification/Statement
Temperature Store below 25 C. Do not freeze.
Packaging Protection Keep in the original container, tightly closed, to protect from moisture and light.
In-Use Stability Discard the medicine 28 days after first opening/reconstitution.
Child Safety Keep out of the sight and reach of children.
Disposal Do not dispose of unused or expired medicine in household waste or wastewater; return it to a pharmacist or official drug take-back location.

These mandated conditions ensure the product remains stable from its manufacturing date through patient use and final, environmentally sound disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Formei found in:

A-Z Index: